DRUG NAME: Cephalexin

• Patient adherence to q6h empty-stomach dosing is unreliable
• Outpatient/PHC settings where simpler regimens improve completion rates
• Mild-to-moderate MSSA skin and soft tissue infections where food-independent absorption is advantageous
• Oral step-down from IV cefazolin (pharmacological class consistency — both first-generation cephalosporins)

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Oral (capsules, tablets, dry syrup/oral suspension, paediatric drops)

---

Biosimilar Status:

---

Formulations Available in India

---

PHARMACOKINETICS

---

Population PK Notes:

---

• Community-acquired E. coli — cephalexin susceptibility: approximately 50–65% (varies by region)
• Community-acquired K. pneumoniae — cephalexin susceptibility: approximately 40–55% (varies)
• These rates are LOWER than in many Western countries due to higher background resistance in India

---

• Cloxacillin/flucloxacillin have lower MICs against MSSA — they are pharmacologically more potent on a per-mg basis. For serious, deep-seated MSSA infections (bacteraemia, endocarditis, osteomyelitis), anti-staphylococcal penicillins are preferred.
• Cephalexin compensates for its higher MICs with its dramatically higher free drug fraction (~85–90% free vs ~4–6% free for cloxacillin). The free drug concentration driving bactericidal activity is therefore more comparable than the total drug concentrations suggest.
• Cephalexin’s food-independent absorption and TDS dosing give it a major practical adherence advantage — and adherence is arguably the single most important determinant of oral antibiotic efficacy in outpatient practice.
• For mild-to-moderate MSSA SSTI, cephalexin is widely considered clinically equivalent to cloxacillin/flucloxacillin in outcome studies — the theoretical potency advantage of the penicillins is offset by better adherence with cephalexin.
• For oral step-down in serious infections (osteomyelitis, bacteraemia follow-on), expert opinion varies:
  • Some ID specialists prefer flucloxacillin 1 g q6h (OVIVA trial precedent)
  • Others use cephalexin 1 g q6h or q8h (simpler regimen, better adherence)
  • API Textbook and AIIMS protocols variably reference both approaches

---

ADULT INDICATIONS + DOSING

---

• UTI (Enterococcus is a common uropathogen, especially in catheterised/complicated UTI)
• Intra-abdominal infections (enterococcal component often present)
• Endocarditis (Enterococcus is a major cause)
  If Enterococcus is suspected or isolated, cephalexin is inappropriate — use ampicillin or amoxicillin.

---

---

Primary Indications (Approved / Standard in India)

---

• Non-purulent cellulitis (no abscess, no pus): Most commonly caused by beta-haemolytic streptococci (Group A — S. pyogenes). Cephalexin provides excellent coverage.
• Purulent SSTI (abscess, furuncle, carbuncle, purulent drainage): Most commonly caused by S. aureus (MSSA or MRSA). If MSSA → cephalexin is appropriate. If MRSA → cephalexin is ineffective.
• ⚠️ In India, distinguish MRSA from MSSA clinically and microbiologically: If the patient has risk factors for CA-MRSA (recurrent boils, household contacts with MRSA, prior MRSA isolation, failure of beta-lactam therapy), obtain wound culture before starting cephalexin. If MRSA is confirmed → switch to cotrimoxazole (TMP-SMX) 960 mg BD, doxycycline 100 mg BD, or clindamycin 300 mg q8h (for community MRSA SSTI).

1. When to prefer cephalexin over alternatives: Cephalexin is preferred over cloxacillin for outpatient oral MSSA/streptococcal SSTI when: (a) Patient adherence to q6h empty-stomach dosing is unlikely (most outpatients), (b) TDS dosing improves compliance, © Food-independent absorption is advantageous. Preferred over amoxicillin-clavulanate when: (a) Infection is purely staphylococcal/streptococcal without anaerobic or resistant Gram-negative concern, (b) Narrower spectrum is preferred (stewardship advantage), © Lower cost is important. IDSA SSTI Guidelines (2014) list cephalexin as first-line oral agent for non-purulent cellulitis. API Textbook references cephalexin as an acceptable first-generation cephalosporin for MSSA SSTI.
2. When NOT to use:
   • ⛔ Suspected or confirmed MRSA → use TMP-SMX, doxycycline, or clindamycin
   • ⛔ Bite wounds (animal or human) → anaerobic component → use amoxicillin-clavulanate
   • ⛔ Diabetic foot infection (polymicrobial) → cephalexin monotherapy is insufficient (Gram-negatives + anaerobes need coverage) → use amoxicillin-clavulanate, or piperacillin-tazobactam for moderate-severe
   • ⛔ Necrotising fasciitis → requires IV broad-spectrum + surgical emergency
   • ⛔ Perianal / perineal SSTI → anaerobic component likely → add metronidazole or use amoxicillin-clavulanate
   • ⛔ Patient with history of anaphylaxis to penicillins — see cross-reactivity guidance (Part 4)
3. NLEM India status: ✔ Cephalexin is included in NLEM India 2022.
4. Typical time to clinical response: 48–72 hours. Cellulitis erythema margins should stop advancing; warmth and tenderness should begin improving. Mark the erythema border with a pen to objectively track progression/regression.
5. Criteria for considering treatment failure and switching:
   • No improvement at 72 hours → (a) reassess diagnosis (is it truly infectious? Consider DVT, contact dermatitis, stasis dermatitis in leg cellulitis), (b) obtain wound culture if not done, © consider MRSA → switch to TMP-SMX/doxycycline/clindamycin, (d) consider deeper infection (abscess, necrotising) → imaging + surgical consultation
   • Worsening despite 48 hours → urgent reassessment, consider IV antibiotics (cefazolin or broader if polymicrobial concern)
6. Mandatory baseline investigations before starting:
   • RECOMMENDED: Wound swab culture and sensitivity (before starting, when feasible — especially if purulent, recurrent, or treatment failure). In PHC settings where culture is unavailable, empiric therapy is acceptable for first episodes of uncomplicated SSTI.
   • OPTIONAL: CBC, blood glucose (screen for diabetes in recurrent SSTI), renal function (if prolonged course planned)
7. Specialist initiation:Not required. Primary care prescribing is appropriate for mild-to-moderate SSTI. Complicated, non-responding, or necrotising SSTI should be referred for surgical and/or ID opinion.
8. Relevant Indian guideline source: API Textbook of Medicine (current edition), Chapter on Skin and Soft Tissue Infections. ICMR Antimicrobial Treatment Guidelines (2022). AIIMS Antibiotic Policy. International: IDSA SSTI Guidelines (Deron et al., 2014) — widely followed in Indian practice.
9. Key disease-specific safety warning: ⚠️ In recurrent SSTI (≥3 episodes in 12 months), consider: (a) nasal MRSA/MSSA decolonisation (mupirocin nasal ointment BD × 5 days + chlorhexidine body wash × 5 days), (b) screen and treat household contacts, © screen for diabetes (very common in Indian patients with recurrent SSTI), (d) assess for immunodeficiency if infections are unusually severe or frequent.
10. Common clinical scenarios where dose adjustment is needed:
    • Renal impairment (eGFR <30): Extend dosing interval — see Part 4
    • Obese patients: Use 500 mg–1 g q6–8h (higher end of range)
    • Elderly: Adjust for renal function; standard dose if eGFR >60

---

1. When to prefer cephalexin: Cephalexin is preferred over amoxicillin-clavulanate for uncomplicated cystitis when the organism is susceptible (cephalexin is narrower-spectrum — stewardship advantage). Preferred when nitrofurantoin is contraindicated (eGFR <30 — nitrofurantoin contraindicated) or when fosfomycin is unavailable/unaffordable. Preferred over fluoroquinolones for uncomplicated cystitis because fluoroquinolones should be reserved for more serious infections (stewardship — ICMR AMR guidelines). Commonly used in pregnancy-associated UTI as a second-line agent (see Pregnancy, Part 4).
2. When NOT to use:
   • ⛔ Complicated UTI (structural abnormality, catheter-associated, recurrent, male UTI, urosepsis) → broader agents preferred (fluoroquinolone, piperacillin-tazobactam, carbapenem — depending on severity)
   • ⛔ Suspected ESBL-producing organism (prior ESBL UTI, recent hospitalisation, recent broad-spectrum antibiotic use) → use nitrofurantoin (still effective against many ESBLs for cystitis) or fosfomycin or carbapenem (for pyelonephritis)
   • ⛔ Enterococcal UTI → cephalexin has NO enterococcal activity → use amoxicillin or ampicillin
   • ⛔ Pseudomonas UTI → no activity → use ciprofloxacin, piperacillin-tazobactam, or aminoglycoside
   • ⛔ Empiric pyelonephritis (first-line) → fluoroquinolone or parenteral agent preferred
   • ⚠️ In India, community E. coli susceptibility to cephalexin is ~50–65% (variable by region) → empiric cephalexin for UTI carries a ~35–50% risk of failure if the organism is resistant → always obtain urine culture
3. NLEM status: ✔ On NLEM.
4. Time to clinical response: Symptom improvement (frequency, dysuria) expected within 24–48 hours. If no improvement by 48–72 hours → suspect resistance → check urine culture results and switch accordingly.
5. Treatment failure criteria: Persistent symptoms at 72 hours; positive repeat urine culture after completing therapy; early recurrence (<2 weeks) → reassess: urine culture, renal imaging (US KUB), consider structural/anatomical cause, consider resistant organism.
6. Mandatory baseline investigations:
   • RECOMMENDED: Urine culture and sensitivity (midstream clean-catch) BEFORE starting antibiotic — especially in India where resistance rates are high. Empiric therapy can be started while awaiting results (culture takes 24–48 hours).
   • MANDATORY (in certain groups): Pregnant women, males, recurrent UTI, complicated UTI, treatment failure → urine culture is MANDATORY before (re)starting therapy.
   • OPTIONAL: Dipstick urinalysis (nitrite + leukocyte esterase) — supportive but not definitive.
7. Specialist initiation: Not required for uncomplicated cystitis — primary care prescribing appropriate. Complicated UTI, pyelonephritis, or recurrent UTI → urology/nephrology/ID referral recommended.
8. Indian guideline source: API Textbook of Medicine; ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2022); AIIMS Antibiotic Policy; International: IDSA/ESCMID Uncomplicated UTI Guidelines (2011/2024 update — widely followed in India).
9. Key disease-specific safety warning: ⚠️ Indian antibiotic resistance context: Fluoroquinolone resistance in community E. coli in India is ~60–75% (very high). Cephalexin resistance is ~35–50%. Nitrofurantoin resistance remains relatively low (~10–20%). Fosfomycin resistance is also low (~5–15%). For empiric uncomplicated cystitis in India, nitrofurantoin remains the best first-line choice (ICMR recommendation) when the patient is not pregnant with eGFR <30. Cephalexin is acceptable but carries a higher empiric failure rate due to Indian resistance patterns.
10. Dose adjustment: Renal impairment → see Part 4 (very important for UTI patients who may already have renal compromise). No dose adjustment needed for hepatic impairment.

---

1. When to prefer cephalexin: (a) Patient has non-anaphylactic penicillin allergy (cephalexin cross-reactivity ~1–2% — see Part 4). (b) Improved adherence desired — BD dosing is simpler than QDS penicillin V. © Treatment failure with penicillin (some evidence of higher bacteriological cure rates with cephalosporins vs penicillin — meta-analysis by Casey & Pichichero). (d) Recurrent GAS pharyngitis — some guidelines suggest cephalosporin course for recurrence after penicillin failure. ⚠️ However, amoxicillin (50 mg/kg/day in 2–3 divided doses × 10 days, or 750 mg–1 g once daily × 10 days in adults) remains the preferred first-line agent in Indian practice (ICMR, IAP).
2. When NOT to use:
   • ⛔ History of anaphylaxis to penicillin → avoid cephalexin (cross-reactivity risk, though low) → use azithromycin 500 mg OD × 5 days (or clindamycin)
   • ⛔ Suspected peritonsillar abscess or deep neck space infection → requires IV antibiotics + surgical drainage
   • ⛔ Non-streptococcal pharyngitis (viral, most cases) → antibiotics NOT indicated; diagnose with Centor/McIsaac score ± rapid antigen detection test (RADT) ± throat culture
3. NLEM status: ✔ On NLEM.
4. Time to response: Symptom improvement (fever, throat pain) within 24–48 hours. If no improvement by 48–72 hours → reassess (peritonsillar abscess? Non-GAS aetiology? Poor adherence?).
5. Treatment failure criteria: Persistent symptoms at 72 hours; positive throat culture after completing therapy (persistent carriage); recurrence within 2–4 weeks of completing therapy.
6. Mandatory baseline investigations:
   • RECOMMENDED: Clinical assessment using Modified Centor / McIsaac Score to estimate GAS probability. RADT (rapid antigen detection test) for GAS if available. Throat culture is the gold standard but takes 24–48 hours — not available at most PHC/CHC settings in India.
   • In resource-limited settings: Treat based on Centor score ≥3 (clinical criteria) if RADT/culture unavailable. The risk of undertreating GAS pharyngitis in India (ARF/RHD prevention) generally outweighs the risk of unnecessary antibiotic exposure.
7. Specialist initiation: Not required — primary care prescribing appropriate. ENT referral for recurrent pharyngitis (≥7 episodes/year or ≥5/year for 2 consecutive years) or peritonsillar abscess.
8. Indian guideline source: API Textbook; IAP guidelines (paediatric pharyngitis — GAS treatment is predominantly a paediatric issue); ICMR AMR guidelines; ICRP (Indian Council of Rheumatic Prevention) — guidelines on ARF/RHD prevention.
9. Key disease-specific safety warning: ⚠️ Do NOT shorten the 10-day course. In India, where RHD burden is enormous, incomplete GAS eradication from the pharynx increases the risk of ARF. Even if symptoms resolve in 2–3 days, the full 10-day course is essential. Counsel patients/families explicitly: “You must take this medicine for the full 10 days, even if you feel completely better after 2–3 days.”
10. Dose adjustment: Renal impairment → adjust per Part 4. No hepatic adjustment needed.

---

1. When to prefer cephalexin: Only when amoxicillin is not tolerated (non-anaphylactic penicillin allergy or GI intolerance) AND cefuroxime axetil and amoxicillin-clavulanate are also unavailable or not tolerated. Cephalexin is pharmacologically inferior to these agents for AOM due to borderline Haemophilus coverage.
2. When NOT to use: ⛔ Suspected mastoiditis or intracranial complication → IV antibiotics; ⛔ Chronic suppurative otitis media (CSOM) → different pathogens, different management; ⛔ History of penicillin anaphylaxis → risk of cross-reactivity with cephalosporins.
3. NLEM status: ✔ On NLEM.
4. Time to response: 48–72 hours.
5. Treatment failure: Persistent symptoms at 72 hours → reassess → switch to amoxicillin-clavulanate or cefuroxime axetil.
6. Mandatory baseline: Otoscopic examination (MANDATORY). Tympanocentesis reserved for complicated/recurrent cases.
7. Specialist initiation: Not required for uncomplicated AOM. ENT referral for complications or recurrent AOM.
8. Indian guideline source: IAP Guidelines (paediatric — AOM is primarily paediatric; adult AOM is less common); API Textbook; International: AAP AOM Guidelines (2013).
9. Key safety warning: ⚠️ Do not confuse AOM with otitis externa (swimmer’s ear) — different aetiology and treatment.
10. Dose adjustment: Renal → Part 4.

---

• ✔ Afebrile for ≥24–48 hours
• ✔ Clinical improvement (local signs improving, WBC trending down, CRP declining)
• ✔ Haemodynamically stable
• ✔ Tolerating oral intake and medications
• ✔ No concern for deep-seated undrained collection
• ✔ Culture confirms susceptible organism (if available)
• ✔ Reliable patient for oral adherence (or caregiver available)

1. When to prefer: This switch is appropriate for virtually ALL indications where IV cefazolin was used for MSSA/streptococcal infections once the patient meets switch criteria. The pharmacological consistency (both first-generation cephalosporins) and cephalexin’s high oral bioavailability (~90–95%) make this a rational and evidence-supported transition.
2. When NOT to use: ⛔ Endocarditis (IV therapy for full duration); ⛔ Meningitis (poor CSF penetration); ⛔ Patient cannot tolerate oral medications (vomiting, ileus); ⛔ Organism is resistant to cephalexin but was susceptible to cefazolin at a higher dose (rare — but check culture).
3. NLEM status: ✔ Both cefazolin and cephalexin on NLEM.
4. Time to response: Already responding (switch occurs AFTER response to IV therapy).
5. Treatment failure after switch: Recurrence of fever/symptoms after switching to oral → consider: (a) inadequate oral absorption (vomiting? diarrhoea?), (b) undrained collection, © organism resistance not detected, (d) need to return to IV.
6. Mandatory baseline: Culture confirmation of susceptible organism (RECOMMENDED before switch). Clinical assessment of readiness for oral switch.
7. Specialist initiation: For straightforward SSTI — primary care can manage the switch. For bacteraemia, osteomyelitis, endocarditis follow-on → ID specialist decision.
8. Indian guideline source: API Textbook; AIIMS Antibiotic Policy; ICMR guidelines support IV-to-oral switch for appropriate infections.
9. Key safety warning: ⚠️ Ensure the patient actually takes the oral antibiotic reliably. The advantage of cephalexin (food-independent, TDS dosing) should be leveraged for adherence. Provide a clear written prescription and follow-up plan.
10. Dose adjustment: Per renal function.

---

1. When to prefer cephalexin: Oral step-down from IV cefazolin for MSSA osteomyelitis/septic arthritis. Preferred over cloxacillin for oral step-down when adherence to empty-stomach q6h dosing is unreliable. Preferred when flucloxacillin is unavailable (common in India). High oral bioavailability (~90–95%) achieves reliable serum levels.
2. When NOT to use: ⛔ MRSA bone/joint infection; ⛔ Polymicrobial osteomyelitis (e.g., post-compound fracture, diabetic foot — need broader coverage); ⛔ TB spondylitis (must be excluded in India — very high prevalence); ⛔ Fungal osteomyelitis (immunocompromised).
3. NLEM status: ✔ On NLEM.
4. Time to response: CRP should decline within 1 week. Pain improvement within 5–7 days.
5. Treatment failure: Rising CRP after initial decline; persistent fever; new imaging abnormalities → reassess (repeat cultures, imaging, surgical re-evaluation).
6. Mandatory baseline: Blood cultures (MANDATORY); bone biopsy culture (RECOMMENDED — gold standard); CRP + ESR (for monitoring); MRI (imaging of choice); renal function.
7. Specialist initiation: ⚠️ MANDATORY. Bone and joint infections must be managed by orthopaedics and/or ID specialist. Oral step-down dose and duration are specialist decisions.
8. Indian guideline source: API Textbook; AIIMS Antibiotic Policy; OVIVA trial (international — increasingly adopted in Indian practice).
9. Key safety warning: ⚠️ At 4 g/day dosing for osteomyelitis, GI side effects (nausea, diarrhoea) are more common. Monitor renal function weekly during prolonged courses. ⚠️ Always exclude TB osteomyelitis in India before starting prolonged anti-staphylococcal therapy.
10. Dose adjustment: Renal impairment — see Part 4 (important at high-dose 4 g/day regimen). Elderly → always check eGFR.

---

Secondary Indications — Adults Only (Off-label, if any)

---

• Non-anaphylactic penicillin allergy (when amoxicillin/amoxicillin-clavulanate cannot be used)
• Superficial dental cellulitis without deep-space involvement (streptococcal predominant)
• In combination with metronidazole 400 mg q8h for mixed aerobic-anaerobic coverage

---

• Prosthetic cardiac valve or prosthetic material for valve repair
• Previous infective endocarditis
• Congenital heart disease (unrepaired cyanotic CHD, repaired with residual defects, within 6 months of repair)
• Cardiac transplant recipients with valvulopathy

---

---

---

---

---

PAEDIATRIC DOSING (Specialist Only)

• ⚠️ All paediatric dosing below is for clinician use only — doses must be calculated and verified by the treating physician or clinical pharmacist before administration.
• Minimum age: Cephalexin can be used from 1 month of age onwards for standard labelled indications. Use in neonates (<28 days) is off-label but practised under neonatologist supervision (see Neonatal Dosing subsection below).
• Minimum weight: No absolute minimum weight. Weight-based dosing (mg/kg) applies. For neonates <2 kg, dosing data is very limited — specialist guidance essential.
• Dosing method: Weight-based (mg/kg/day divided into doses) — preferred for all paediatric age groups.
• Dosing convention:
  • Doses are expressed as mg/kg/day (total daily dose) divided into 2, 3, or 4 doses — OR as mg/kg/dose with frequency specified
  • This monograph uses mg/kg/dose with frequency for clarity
• Maximum absolute dose (adult ceiling): Regardless of the child’s weight, do NOT exceed adult maximum doses:
  • Standard infections: Max 500 mg per dose; Max 2 g per day
  • Serious infections (osteomyelitis step-down): Max 1 g per dose; Max 4 g per day
• Adolescent transition: Children ≥12 years AND ≥40 kg → use adult dosing. If the adolescent weighs <40 kg despite being ≥12 years, continue weight-based dosing.

• ✔ Dry syrup / Oral suspension (125 mg/5 mL, 250 mg/5 mL): The primary formulation for paediatric use. Widely available across India from multiple manufacturers. Reconstitute with water before use (see Reconstitution section below).
  • ⚠️ Palatability: Cephalexin suspension has a mildly sweet, fruity flavour (most manufacturers add flavouring — strawberry, orange, or mixed-fruit). It is significantly more palatable than cloxacillin suspension (which is notoriously bitter). This is a meaningful practical advantage for paediatric adherence.
  • ℹ️ Palatability varies by manufacturer — some brands taste better than others. Parents/caregivers should be counselled that the child may initially resist the taste but can usually be given the medicine mixed with a small amount of juice or sweetened drink immediately before administration (unlike cloxacillin/flucloxacillin, which cannot be mixed with food due to absorption concerns — cephalexin has no food-effect restriction).
  • ✔ Can be administered via nasogastric tube — shake well, draw up measured dose with oral syringe, flush tube with 5–10 mL water before and after.
• ✔ Paediatric drops (125 mg/1.25 mL = 100 mg/mL): For infants and very young children where smaller volumes are preferred. Limited availability from select manufacturers — not all pharmacies stock this formulation. If unavailable, use the standard oral suspension (125 mg/5 mL) with a calibrated oral syringe for accurate small-volume dosing.
• ✔ Capsules (250 mg, 500 mg): For older children (typically ≥8–10 years) who can swallow capsules whole. Capsules should be swallowed intact with water. If a child cannot swallow capsules, the capsule may be opened and contents mixed with a small amount of soft food (jam, yogurt, applesauce) — unlike cloxacillin, cephalexin absorption is NOT impaired by food. However, the powder is somewhat gritty and may have a mild bitter taste — mix thoroughly and consume immediately. This is an off-label administration method but widely practised.
• ✔ Dispersible tablets (250 mg, 500 mg — select manufacturers): Can be dispersed in a small volume of water (10–20 mL) for children who cannot swallow tablets. Suitable for enteral tube administration. Limited availability in India.

• Monitor for GI intolerance (diarrhoea, nausea, vomiting) — the most common adverse effects; usually mild and self-limiting
• For prolonged courses (>2 weeks): monitor CBC, renal function at baseline and periodically
• ⚠️ Oral candidiasis (thrush): Common in young children and infants on oral cephalexin courses >7 days. Inspect oral cavity; treat with nystatin oral drops if symptomatic.
• ⚠️ Nappy/diaper candidiasis: Common in infants. Treat with topical clotrimazole or nystatin cream.
• ⚠️ Antibiotic-associated diarrhoea (AAD): More common in children than adults. Usually mild. If severe, bloody, or accompanied by fever → evaluate for CDI (uncommon in young children but possible, especially in hospitalised paediatric patients).
• For cephalexin’s favourable safety profile, routine laboratory monitoring is NOT necessary for standard short courses (5–10 days) in otherwise healthy children.

---

NEONATAL DOSING (Separate Subsection)

---

Primary Indications — Paediatric (Approved / Standard in India)

---

• Impetigo in Indian children is overwhelmingly due to S. aureus (MSSA) and/or S. pyogenes (GAS) — both well-covered by cephalexin
• For simple, small impetigo lesions (<3 lesions, limited area): topical mupirocin 2% or fusidic acid 2% applied TDS for 5 days may suffice without oral antibiotics
• Screen for scabies in children presenting with secondary bacterial infection of skin — treat scabies concomitantly (permethrin 5% cream)
• ⚠️ In India, community-acquired MRSA (CA-MRSA) in children is increasingly reported, particularly in urban settings. If SSTI fails to respond to cephalexin at 72 hours, or if the child has recurrent abscesses → obtain wound culture → consider TMP-SMX or clindamycin for CA-MRSA
• IAP guidelines recommend first-generation cephalosporins (cephalexin) as acceptable first-line oral agents for MSSA SSTI in children

---

• Non-anaphylactic penicillin allergy
• Treatment failure with amoxicillin (persistent symptoms or positive throat culture after completing amoxicillin course)
• Recurrent GAS pharyngitis (some evidence of superior bacteriological eradication with cephalosporins in recurrence — Casey & Pichichero meta-analysis, 2007)
• BD cephalexin may improve adherence in school-going children compared to TDS amoxicillin (though amoxicillin also supports BD dosing)

• ⚠️ Full 10-day course is essential. Indian parents frequently stop antibiotics when the child feels better (usually day 2–3). This is the single biggest barrier to ARF prevention. Counsel emphatically at the time of prescribing.
• Use the Modified Centor / McIsaac Score to assess clinical probability of GAS pharyngitis — do NOT prescribe antibiotics for probable viral pharyngitis
• RADT (rapid antigen detection test for GAS) is increasingly available at some Indian paediatric clinics — use if available to confirm diagnosis
• In resource-limited settings without RADT/throat culture: Treat clinically based on McIsaac score ≥3 (especially in children with high fever, tonsillar exudate, tender anterior cervical lymphadenopathy, absence of cough)
• Rheumatic fever prophylaxis: Cephalexin is NOT used for secondary ARF prophylaxis (benzathine penicillin G injection every 3–4 weeks is the standard). Cephalexin is only for treatment of acute GAS pharyngitis (primary prevention of ARF).

---

• ⚠️ Urine culture is MANDATORY in all paediatric UTI (IAP guidelines) — unlike adult uncomplicated cystitis where empiric therapy without culture is sometimes acceptable. Paediatric UTI requires imaging workup (USG KUB at minimum) for structural abnormalities, especially first episode in children <2 years.
• Method of urine collection matters: Bag urine specimens have high contamination rates → suprapubic aspiration (gold standard in infants) or catheter specimen for young children; midstream clean-catch for toilet-trained children
• In India, community-acquired E. coli resistance to cephalexin in paediatric UTI is ~30–45% — always send culture and adjust therapy accordingly
• Enterococcal UTI in children (not uncommon, especially in those with structural abnormalities) → cephalexin has NO enterococcal activity → use amoxicillin
• IAP UTI guidelines recommend cephalexin as a second-line option for acute paediatric UTI treatment and as an option for UTI prophylaxis

---

• IAP guidelines and AAP guidelines both recommend amoxicillin as first-line
• For treatment failure at 48–72 hours with amoxicillin → switch to amoxicillin-clavulanate (not cephalexin) — the failure is often due to H. influenzae or beta-lactamase-producing M. catarrhalis, which cephalexin covers poorly
• Cephalexin’s role in paediatric AOM is limited — primarily for children with non-anaphylactic penicillin allergy when amoxicillin-clavulanate and cefuroxime axetil are also unavailable
• Observation without antibiotics (“watchful waiting”) is an option for mild AOM in children ≥2 years with unilateral disease — discuss with parents

---

• Cephalexin is an excellent oral step-down agent after IV cefazolin for paediatric MSSA osteomyelitis/septic arthritis
• IAP guidelines and the Finnish paediatric osteomyelitis RCTs (Peltola et al.) support:
  • Short IV courses (3–5 days) followed by oral step-down
  • Shorter total courses (3–4 weeks for uncomplicated osteomyelitis; 2–3 weeks for septic arthritis) than traditionally used
  • Serial CRP is the best monitoring marker — CRP should decline by >50% from peak before oral switch and continue declining during oral therapy
• ⚠️ In children <5 years, Kingella kingae is an important pathogen for bone/joint infections — NOT well covered by cephalexin → use amoxicillin-clavulanate if Kingella is suspected
• ⚠️ Always exclude TB osteomyelitis in India — histopathology/GeneXpert from bone biopsy
• Cephalexin’s food-independent absorption and palatable suspension formulation make it an ideal oral step-down agent for paediatric bone infections — superior adherence profile compared to cloxacillin (which requires empty-stomach q6h dosing and has a bitter-tasting suspension)

---

Secondary Indications — Paediatric (Off-label, if any)

---

• 5–10 mg/kg/dose oral, once daily at bedtime
• Max 250 mg per dose
• Duration: months to years (until VUR resolves or surgical correction — specialist decision)

• First-line prophylactic agents: nitrofurantoin (1–2 mg/kg OD) or TMP-SMX (1–2 mg/kg TMP OD)
• Cephalexin is an alternative when nitrofurantoin/TMP-SMX is not tolerated, contraindicated, or the organism is resistant
• Preferred in neonates and young infants <2 months (nitrofurantoin is contraindicated in first month; TMP-SMX should be avoided in first 6 weeks due to kernicterus risk)

---

• 50 mg/kg oral (single dose), 30–60 minutes before dental procedure
• Max dose: 2 g (adult ceiling)

---

• Children <8 years (tetracyclines contraindicated due to dental staining)
• In practice, acne requiring oral antibiotics in children <8 years is uncommon — if needed, specialist (dermatologist) guidance essential
• In adolescents ≥12 years who cannot tolerate tetracyclines

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

Structured by dosing frequency:

---

---

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

• ✔ Best practice: Store reconstituted suspension in the refrigerator. If the family has a refrigerator, this is the standard advice.
• ⚠️ If no refrigerator is available (common in rural India and urban slum populations):
  • Store in the coolest part of the house (away from kitchen, direct sunlight, and heat sources)
  • Wrap the bottle in a damp cloth (evaporative cooling)
  • Use within 5–7 days rather than the label-stated 14 days
  • Consider prescribing the capsule formulation instead (if the child can swallow capsules, or if capsules can be opened and contents mixed with food) — dry capsules are stable at room temperature and are not temperature-sensitive

---

---

---

• ✔ Capsules and dry powder (before reconstitution) are stable at Indian room temperature (<30°C) and do NOT require cold storage
• ⚠️ During extreme summer (>40°C in many Indian cities), store capsules in the coolest room, away from the kitchen and windows. Use a cotton or cloth pouch to protect from humidity (especially in coastal/humid areas)
• ⚠️ Reconstituted suspension MUST be refrigerated if possible. If no refrigerator → use within 5–7 days and store in the coolest available location
• ⚠️ Do NOT freeze any formulation of cephalexin — freezing damages the suspension formulation irreversibly

---

RENAL ADJUSTMENT

---

---

• Use the higher end of dosing (500 mg–1 g q6h)
• Consider extended infusion of IV cefazolin instead if adequate oral levels are uncertain
• ARC is transient — standard dosing can be resumed as the hyperdynamic state resolves

---

HEPATIC ADJUSTMENT

• ✔ No hepatic dose adjustment is required — at any degree of hepatic impairment (Child-Pugh A, B, or C)
• ✔ Hepatic failure, cirrhosis, and hepatocellular disease do NOT alter cephalexin clearance
• ✔ No active metabolites exist — no risk of metabolite accumulation in liver disease
• ✔ Protein binding is very low (~10–15%) — hypoalbuminaemia in cirrhosis does NOT meaningfully alter free drug levels (already ~85–90% free in normal albumin)
• ✔ Cephalexin has very low intrinsic hepatotoxicity — it is one of the safest antibiotics from a hepatic perspective

• Rifampicin co-administration: No pharmacokinetic interaction (cephalexin is not a CYP substrate). No additive hepatotoxicity concern. No dose adjustment needed.
• Isoniazid / Pyrazinamide co-administration: No pharmacokinetic interaction. No additive hepatotoxicity concern. Can be co-prescribed safely.
• Methotrexate co-administration: See Drug Interactions — renal tubular secretion competition (OAT-mediated) is the concern, NOT hepatotoxicity.
• Valproate co-administration: No interaction.
• Antiretrovirals: No hepatic interaction. No concern for additive hepatotoxicity.

---

CONTRAINDICATIONS

---

• Non-allergic GI side effects (nausea, diarrhoea)
• Non-specific childhood rash (may have been viral exanthem coinciding with antibiotic use)
• Family history of allergy (not personal)
• Vague/undocumented history

• Inappropriate avoidance of beta-lactams (the safest, most effective, and cheapest antibiotic class)
• Use of broader-spectrum or more expensive alternatives (fluoroquinolones, macrolides, carbapenems) → increased AMR
• Denial of optimal therapy (e.g., penicillin for syphilis, amoxicillin for GAS pharyngitis)

• What happened? (Describe exact symptoms)
• How soon after taking the medicine? (Minutes = possible IgE-mediated; days = delayed)
• Did it require emergency treatment? (Adrenaline, hospitalisation?)
• How long ago?
• Has the patient ever taken any other penicillin or cephalosporin since then without a reaction?

---

CAUTIONS

---

---

PREGNANCY

---

LACTATION

---

ELDERLY

---

MAJOR DRUG INTERACTIONS

---

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

---

---

SERIOUS ADVERSE EFFECTS

---

---

• Skin rash of any kind — especially if spreading, blistering, or involving mouth/eyes/genitals
• Swelling of face, lips, tongue, or throat; difficulty breathing (anaphylaxis warning)
• Severe or bloody diarrhoea (CDI warning)
• Unusual tiredness, pale skin, dark urine, yellowing of eyes (haemolytic anaemia — very rare)
• Significant reduction in urine output (renal — very rare)

---

MONITORING REQUIREMENTS

---

• If renal function cannot be tested: Enquire about known kidney disease, diabetes, use of nephrotoxic drugs. Assess urine output. Use standard dosing with clinical vigilance in healthy young patients. Refer for renal function testing if prolonged course is planned.
• If cultures unavailable (common in PHC/CHC): Empiric therapy is acceptable for first-episode uncomplicated infections. Refer for culture if treatment failure or recurrence.

---

---

---

• Short courses (≤10 days) in healthy patients: No ongoing monitoring needed after completion.
• Prolonged courses: Stop monitoring (CBC, renal) at course completion if values were stable throughout.
• UTI follow-up cultures: Single post-treatment culture at 1–2 weeks is usually sufficient.

---

PATIENT COUNSELLING

---

---

• “You can take this medicine with food or on an empty stomach — either is fine. Taking it with food may help if you feel sick (nauseous) after taking it.”
• “Swallow the capsule whole with a full glass of water (at least one cup).”
• “If you are taking the liquid (syrup) form, shake the bottle well before each dose. Use the measuring cup or syringe provided — do NOT use a household teaspoon.”
• “Try to take your doses at evenly spaced times through the day. For example, if you take it 3 times a day — take it morning, afternoon, and bedtime.”
• “You can take this medicine with milk, tea, juice, or food — there is no restriction.”

---

---

• “Loose motions (diarrhoea) — this is the most common side effect. The medicine kills some good bacteria in your stomach along with the bad ones. Drink plenty of water and ORS. If the loose motions are very bad, watery, or have blood — come to the hospital.”
• “Mild nausea or stomach discomfort — taking the medicine with food usually helps.”
• “White patches in the mouth (thrush) or itching in the private area — this is a yeast infection caused by the medicine killing good bacteria. It can be easily treated — tell your doctor.”

---

• “Skin rash — especially if it is spreading, has blisters, or involves your mouth, eyes, or private parts”
• “Swelling of your face, lips, tongue, or throat / difficulty breathing — this could be a serious allergic reaction”
• “Severe diarrhoea — more than 6 watery stools a day, or diarrhoea with blood or severe stomach cramps”
• “Very little urine or no urine at all”
• “Yellow colour in your eyes or skin (very rare with this medicine, but report it)”
• “Unusual tiredness, pale skin, or dark urine”

---

• “There are no specific foods to avoid with this medicine. You can eat and drink normally.”
• “You can take this medicine with milk and dairy products — no problem (unlike some other antibiotics).”
• “Avoid drinking excessive alcohol — it may worsen stomach problems and is not helpful while fighting an infection.”

---

• “Keep capsules/tablets in a cool, dry place below 30°C. Do NOT store in the bathroom.”
• “If using the liquid (syrup): keep it in the fridge after mixing. Use within 14 days (or 7 days if no fridge is available). Write the date of preparation on the bottle.”
• “In hot weather, keep medicine away from direct sunlight and heat.”
• “Keep all medicines out of reach of children.”

---

• “Take the full course of medicine as prescribed by your doctor, even if you feel better after 2–3 days.”
• “Stopping early can cause the infection to come back, and the germs may become harder to treat next time.”
• “This is especially important for throat infections — you must take the medicine for a full 10 days to protect your heart from a complication called rheumatic fever.”
• “Do NOT save leftover capsules or syrup for future use — antibiotics should only be taken when prescribed by a doctor.”

---

• “Come back for review as advised by your doctor — usually after 3–5 days for skin infections, or sooner if your symptoms are not improving.”
• “If your doctor has asked for a urine test after finishing the medicine, please get it done — this checks whether the infection is fully cleared.”

---

---

• Correct dose measurement: “Always shake the bottle well. Use the measuring cup or oral syringe provided — do NOT use a household spoon (doses will be inaccurate).”
• Giving medicine to a reluctant child: “The syrup has a fruity taste but some children may still resist. You can mix the measured dose with a small amount of juice, milk, or soft food (jam, yogurt) and give it immediately. Unlike some other antibiotics, this medicine can be mixed with food without any problem.”
• Completing the full course: “Even if your child seems completely well after 2–3 days, give ALL the medicine as prescribed. For throat infections — the full 10 days is essential to protect the heart.”
• Vomiting after dose: “If your child vomits within 30 minutes of taking the medicine, give the dose again. If vomiting happens after 30 minutes, do NOT give extra.”
• Storing the liquid: “Keep in the fridge after mixing. If no fridge: keep in the coolest part of the house and use within 5–7 days.”
• Warning signs: “Bring the child/patient to the hospital immediately if you notice: skin rash, blisters, swelling of face or lips, blood in stool, the child is not feeding, or seems more sick instead of getting better.”

---

---

BRANDS AVAILABLE IN INDIA

---

• Jan Aushadhi Cephalexin Capsules 250 mg — available at PMBJP stores
• Jan Aushadhi Cephalexin Capsules 500 mg — available at PMBJP stores
• Jan Aushadhi Cephalexin Dry Syrup 125 mg/5 mL — available at select PMBJP stores (verify availability at your nearest store)

---

---

PRICE RANGE (INR)

---

---

---

CLINICAL PEARLS

---

---

---

---

---

---

---

VERSION

---

REFERENCES

1. CDSCO Product Inserts — Sporidex (cephalexin), Sun Pharmaceutical Industries; Phexin (cephalexin), GSK Pharmaceuticals India; Ceff (cephalexin), Lupin Limited. Revision dates not uniformly available; data extracted from the most recently accessible package inserts (accessed 2024).
2. Indian Pharmacopoeia (IP) 2022, Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Cephalexin (Cefalexin) — identity, assay, standards.
3. National List of Essential Medicines (NLEM) India 2022, Ministry of Health & Family Welfare, Government of India. Cephalexin listed under Section 6.2 — Antibacterials (beta-lactam medicines, cephalosporins).
4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Brunton LL, Hilal-Dandan R, Knollmann BC (Eds). Chapter 58: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. Used for pharmacology depth, PK parameters, spectrum of activity, mechanism of action, and drug interaction data.
5. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (Eds). Chapters on: Skin and Soft Tissue Infections, Urinary Tract Infections, Pharyngitis, Osteomyelitis, Infective Endocarditis. Used for disease management context and clinical indications.
6. API Textbook of Medicine, 12th Edition (2022). Association of Physicians of India. Chapters on: Antimicrobial Therapy, Skin and Soft Tissue Infections, Urinary Tract Infections, Streptococcal Infections, Rheumatic Fever. Used for Indian clinical practice context.
7. IAP (Indian Academy of Pediatrics) Guidelines — Drug Formulary and Treatment Guidelines for paediatric infections; IAP Guidelines on GAS Pharyngitis and ARF prevention; IAP UTI Guidelines; IAP AOM Guidelines. Year: 2019–2023 guidelines.
8. NNF (National Neonatology Forum) India — Drug Doses handbook (latest edition). Referenced for neonatal dosing principles (limited specific data for cephalexin).
9. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019, updated 2022). Indian Council of Medical Research. Used for India-specific empiric antibiotic recommendations, resistance patterns, and UTI management.
10. ICMR Antimicrobial Resistance Surveillance Network — Annual Reports (2022–2023). Used for Indian resistance data for E. coli, K. pneumoniae, and S. aureus against cephalexin.
11. AIIMS Antibiotic Policy — All India Institute of Medical Sciences, New Delhi. Referenced for institutional antibiotic recommendations and IV-to-oral switch protocols.
12. IDSA SSTI Guidelines — Stevens DL, Bisno AL, Chambers HF, et al. “Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America.” Clin Infect Dis. 2014;59(2):e10-e52. Used for SSTI classification, treatment recommendations, and duration guidance.
13. IDSA/ESCMID Uncomplicated UTI Guidelines — Gupta K, Hooton TM, Naber KG, et al. “International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the IDSA and ESCMID.” Clin Infect Dis. 2011;52(5):e103-e120. (2024 update also referenced for current recommendations.) Used for UTI treatment hierarchy and cephalexin’s role as a second-line agent.
14. DANCE Trial — Dan JM, et al. “Clinical Cure with 5 Days versus 10 Days of Antibiotics for Uncomplicated Cellulitis.” Clin Infect Dis. 2017. Referenced for short-course cellulitis evidence.
15. Pichichero ME, Casey JR. “Comparison of cephalosporin and penicillin treatment of group A streptococcal pharyngitis.” Multiple publications (Pichichero et al., 2000; Casey & Pichichero, 2004, 2007). Used for evidence supporting BD cephalexin for GAS pharyngitis and cephalosporin vs penicillin meta-analysis.
16. OVIVA Trial — Li HK, Rombach I, Zamber R, et al. “Oral versus Intravenous Antibiotics for Bone and Joint Infection.” N Engl J Med. 2019;380(5):425-436. DOI: 10.1056/NEJMoa1710926. Referenced for oral step-down evidence in bone/joint infections.
17. Peltola H, Pääkkönen M, et al. Paediatric osteomyelitis RCTs — “Short- versus Long-Term Antimicrobial Treatment for Acute Hematogenous Osteomyelitis of Childhood.” Pediatr Infect Dis J. 2010;29(12):1123-1128. And: “Prospective, Randomized Trial for Childhood Septic Arthritis.” Clin Infect Dis. 2009. Used for paediatric bone/joint infection duration and oral step-down evidence.
18. AHA IE Prophylaxis Guidelines — Wilson WR, Taubert KA, Gewitz M, et al. “Prevention of Infective Endocarditis: Guidelines from the AHA.” Circulation. 2007 (updated 2021). Used for IE prophylaxis indications and cephalexin dosing.
19. FOGSI (Federation of Obstetric & Gynaecological Societies of India) Guidelines — UTI in pregnancy management. Referenced for cephalexin use in pregnancy UTI.
20. WHO Mastitis Guidelines — Mastitis: Causes and Management. WHO/FCH/CAH/00.13. Referenced for mastitis treatment.
21. RIVUR Trial — “Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux.” N Engl J Med. 2014;370(25):2367-2376. Referenced for UTI prophylaxis in VUR.
22. NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) and NPPA ceiling prices for NLEM drugs. Accessed 2024–2025.
23. PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Jan Aushadhi product catalogue. Reviewed to confirm cephalexin availability and estimated pricing. Accessed 2024–2025.
24. PvPI (Pharmacovigilance Programme of India) — CDSCO. Referenced for ADR reporting mechanisms and pharmacovigilance requirements.

---